



# GLAND PHARMA LIMITED

October 25, 2021

BSE Limited  
Corporate Relationship Department  
Phiroze Jeejeebhoy Towers  
25<sup>th</sup> floor, Dalal Street  
Mumbai - 400 001  
Scrip Code: 543245

National Stock Exchange of India Limited  
Listing Department  
Exchange Plaza, 5th floor  
Plot no. C-1, Block G, Bandra Kurla Complex Bandra  
(East), Mumbai - 400 051  
Symbol : GLAND (ISIN : INE068V01023)

Dear Sir/Madam,

**Sub: Report of the Monitoring Agency for the Quarter ending September 30, 2021**

Pursuant to Regulation 41(4) of SEBI (Issue of Capital and Disclosure Requirements) Regulations, 2018 and Regulation 32(6) of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, please find enclosed herewith Monitoring Agency Report dated October 25, 2021 in respect of utilization of proceeds of IPO for the quarter ended September 30, 2021 issued by M/s. Axis Bank Limited, Monitoring Agency.

This is for your information and records.

Yours truly,

For Gland Pharma Limited



**Sampath Kumar Pallerlamudi**  
Company Secretary

Encl: As mentioned above

**Regd. Office:**

Survey No. 143-148, 150 & 151, Near Gandimaisamma 'X' Roads  
D.P. Pally, Dundigal, Dundigal-Gandimaisamma Mandal  
Medchal-Malkajgiri District, Hyderabad 500043, Telangana, India  
Tel: +91-40-30510999 Fax: +91-40-30510800

**Corporate Office:**

Plot No. 11 & 84, TSIC Phase: IV  
Pashamylaram (V), Patancheru (M), Sangareddy District  
Hyderabad 502307, Telangana, India  
Tel: +91-8455-699999

**AXB/CO/IFB-TS/2021-22/103**

October 25, 2021

**To,**

**Gland Pharma Limited**

Sy. No. 143-148, 150 and 151

Near Gandhi Maisamma 'X' Roads, D.P.Pally

Dundigal, Hyderabad – 500043

Dear Sir,

**Sub: Gland Pharma Limited (the Company) – Monitoring Agency Report**

We write in our capacity of Monitoring Agent to the Company and refer to our duties cast under Regulation 41(2) of the Securities & Exchange Board of India (Issue of Capital & Disclosure Requirements) Regulations, 2018.

In terms of above, please find attached the Monitoring Report for the quarter ended on September 30, 2021 as per Schedule XI of the aforesaid SEBI Regulations.

Request you to kindly take the same on records.

Thanking you.

**For and on behalf of Axis Bank Ltd**



**Authorized Signatory**

Corporate Office :

Axis Bank Limited, 'Axis House', C-2, Wadia International Centre,  
Pandurang Budhkar marg, Worli, Mumbai - 400 025.

[www.axisbank.com](http://www.axisbank.com)



**AXIS BANK**

## Report of the Monitoring Agency

Name of the Issuer: **Gland Pharma Limited**

For Quarter ended: **30<sup>th</sup> September, 2021**

Name of the Monitoring Agency: **Axis Bank Limited**

(a) Deviation from the objects: **No deviation from objects**

(b) Range of Deviation: **Not applicable**

Declaration:

We declare that this report is based on the format as prescribed by SEBI (ICDR) Regulations, 2018, as amended. We further declare that this report provides a true and fair view of the utilization of issue proceeds.

We declare that we do not have any direct / indirect interest in or relationship with the issuer/promoters/directors/management and also confirm that we do not perceive any conflict of interest in such relationship / interest while monitoring and reporting the utilization of issue proceeds by the issuer. We also declare that the certificate is provided on the basis of management representation and certification provided by the statutory auditor of the Company.

**For and on behalf of Axis Bank Ltd**



---

**Name:** Mangalagowri Bhat

**Date:** October 25, 2021

**Issuer Details:**

Name of the issuer : Gland Pharma Limited  
The name of the promoter of the issuer : Fosun Pharma Industrial Pte. Ltd. and Shanghai Fosun Pharmaceutical (Group) Co. Ltd.  
Industry/sector to which it belongs : Pharmaceutical

**1) Issue Details:**

Issue Period : November 9, 2020 to November 11, 2020  
Type of Issue (public/rights) : Initial Public Offer  
Type of specified securities : Equity Shares  
Issue size (INR in Millions) : 64,795.45

**2) Details of the arrangement made to ensure the monitoring of issue proceeds:**

Particulars	Reply	Comments of Monitoring Agency	Comments of the Board of Directors
Whether all the utilization is as per disclosure in Offer Document?	Yes/No	Yes	Yes
Whether Shareholder approval is obtained in case of material deviations# from expenditures disclosed in Offer Document?	Yes/No	Not applicable	Not applicable
Whether means of finance for disclosed objects of the Issue has changed?	Yes/No	No	No
Any major deviation observed over the earlier monitoring agency reports?	Yes/No	Not applicable	Not applicable
Whether all Government / Statutory approvals related to the object(s) obtained?	Yes/No	Not applicable	Not applicable
Whether all arrangements pertaining to technical assistance/collaboration are in operation?	Yes/No	Not Applicable	Not Applicable
Any favorable events improving object(s) viability	Yes/No	Not Applicable	Not Applicable
Any unfavorable events affecting object(s) viability	Yes/No	No	No
Any other relevant information that may materially affect the decision making of the investors	Yes/No	Not Applicable	Not Applicable

# Where material deviation may be defined to mean:

- a) Deviation in the objects or purposes for which the funds have been raised;  
b) Deviation in the amount of funds actually utilized by more than 10% of the amount projected in the offer documents.

**4) Details of object(s)s to be monitored:**

- (i) Cost of objects-

Particulars	Amount in INR. Million
Gross Proceeds from the Fresh Issue	12,500.00
(Less) Offer expenses*	250.00
Net Proceeds	12,250.00

\* The Offer expenses is agreed to be shared in the proportion of Equity Shares sold by the Selling Shareholders and offered by the Company. As per the Prospectus, the total offer expenses are estimated to be INR 1,392.52 million (including GST), out of which company's share is INR 250.00 Million, based on the proportion of equity shares offered by the Company. In the current quarter IPO expenses has been actualised based on the bills received.

(Give Item by Item Description for all the Objects Stated in Offer Document separately in following format)

Sl. No	Item Head	Original Cost (as per Offer	Revised Cost	Comments of	Comments of the Board of Directors		
					Reason of cost	Proposed	Particulars of

		Document) INR In millions	INR In millions	Monitoring Agency	revision	financing option	firm arrangements made
1	Funding incremental working capital requirement	7,695.00	7695.00	NA	NA	NA	NA
2	Funding capital expenditure requirements	1,680.00	1680.00	NA	NA	NA	NA
3	General corporate purpose#	2,864.68	2875.00	Surplus on account of actual bills received for IPO expenses	Surplus on account of actual bills received for IPO expenses	NA	NA
	<b>Total</b>	<b>12,239.68</b>	<b>12,250.00</b>				

# During the quarter (ending 31-Mar-21), the actual issue expenditure concluded at INR 250.00 Mn as against estimated amount of INR 260.32 Mn, pursuant to which the unutilised portion of issue expenses of INR 10.32 Mn has been added to the Net proceeds for general corporate purpose resulting in balance available for utilisation being revised to INR 2,875 Mn.

(ii) Progress in the objects-

(Give Item by Item Description for all the Objects Stated in Offer Document separately in the following format) – INR in millions

Sl. No	Item Heads	Net Proceeds	Amount utilized			Total unutilized Amount	Comments of Monitoring Agency	Comments of the Board of Directors	
			As at Beginning of the quarter	During the quarter	At the end of the quarter			Reason of idle funds	Proposed Course of Action
1	Incremental working capital requirement	7,695.00	5,329.52	1,074.17	6,403.69	1,291.31	NA	NA	NA
2	Capital expenditure requirement	1,680.00	369.87	193.49	563.36	1,116.64	NA	NA	NA
3	General corporate purpose*	2,875.00	2,875.00	-	2875.00	-	NA	NA	NA
	<b>Total</b>	<b>12,250.00</b>	<b>8,574.39</b>	<b>1,267.66</b>	<b>9,842.05</b>	<b>2,407.95</b>			

(a) Name of the object(s): Incremental working capital

(b) Brief description of the object(s): Incremental working capital requirement of the Company

(c) Location of the object(s) (if applicable): Not applicable

(a) Name of the object(s): Capital expenditure requirement

(b) Brief description of the object(s): Capital requirement of the Company

(c) Location of the object(s) (if applicable): Not applicable

(a) Name of the object(s): General corporate purpose

(b) Brief description of the object(s): General corporate expenses of the Company

(c) Location of the object(s) (if applicable): Not applicable

\* Pursuant to Regulation 41(2) of SEBI (ICDR) Regulations Monitoring Agency is not commenting on the utilization of issue proceeds under the head General Corporate Purpose.

(iii) Deployment of unutilised Issue proceeds: INR in millions

Sl.No	Type of instrument and name of the entity invested in	Amount invested	Maturity Date	Earning	Return on Investment (ROI %)	Market Value as at the end of quarter*
1	Fixed deposit- Axis Bank	17.50	13-Oct-21	Nil	4.40%	17.50
2	Fixed deposit- Axis Bank	17.50	13-Oct-21	Nil	4.40%	17.50
3	Fixed deposit- Axis Bank	15.00	13-Oct-21	Nil	4.40%	15.00
4	Fixed deposit- Axis Bank	17.50	29-Oct-21	Nil	4.40%	17.50
5	Fixed deposit- Axis Bank	17.50	29-Oct-21	Nil	4.40%	17.50
6	Fixed deposit- Axis Bank	15.00	29-Oct-21	Nil	4.40%	15.00
7	Fixed deposit- Axis Bank	17.50	15-Nov-21	Nil	4.40%	17.50
8	Fixed deposit- Axis Bank	17.50	15-Nov-21	Nil	4.40%	17.50
9	Fixed deposit- Axis Bank	15.00	15-Nov-21	Nil	4.40%	15.00
10	Fixed deposit- Axis Bank	17.50	29-Nov-21	Nil	4.40%	17.50
11	Fixed deposit- Axis Bank	17.50	29-Nov-21	Nil	4.40%	17.50





142	Monitoring Account- Axis Bank	7.95	NA	NA	NA	7.95
	<b>Total</b>	<b>2,407.95</b>				<b>2,407.95</b>

\* Where the market value is not feasible, provide NAV/NRV/Book Value of the same

The company has earned an interest of INR 113.21 Million on fixed deposits matured up-to the period ended September 30, 2021

(iv) Delay in implementation of the object(s): Not applicable

Object(s)	Completion Date		Delay (no. of days/ months)	Comments of the Board of Directors	
	As per the Offer Document	Actual*		Reason of delay	Proposed course of action
Not applicable					

\* In case of continuing object(s), please specify latest/revised estimate of the completion date.